UC Berkeley's Nurix Therapeutics will use the capital to prepare two protein modulation-based immuno-oncology drugs for the clinic.
Nurix Therapeutics, a US-based cancer drug developer spun out of University of California (UC), Berkeley, has completed a $120m round led by life sciences investment firm Foresite Capital.
Incubator and venture firm Third Rock Ventures also contributed to the round, as did Bain Capital’s Life Sciences unit, Tavistock Group’s Boxer Capital, EcoR1 Capital, Redmile Group, Wellington Management, Column Group and one undisclosed investor.
Founded in 2009 as Kura Therapeutics, Nurix develops cancer drugs that modulate production of specific…
